Business UpdateJun 2, 2026, 04:38 PM
Nanobiotix Raises €86.1M; Reports Strong Phase 2 NSCLC Data
AI Summary
Nanobiotix provided its first-quarter 2026 operational and financial update, highlighting a successful follow-on offering in May 2026 that raised approximately €86.1 million in gross proceeds. This funding, combined with €42.1 million in cash as of March 31, 2026, is projected to support operations into 2029. The company also reported positive new data from its Phase 2 CONVERGE study for JNJ-1900 (NBTXR3) in NSCLC, showing high response rates, and announced FDA acceptance of a protocol amendment to accelerate the pivotal NANORAY-312 study.
Key Highlights
- Completed a follow-on offering in May 2026, raising approximately €86.1 million in gross proceeds.
- Cash and cash equivalents totaled €42.1 million as of March 31, 2026.
- Net proceeds from the offering and existing cash are expected to fund operations into 2029.
- Phase 2 CONVERGE study for JNJ-1900 (NBTXR3) in NSCLC showed an 85.7% overall response rate and 57.1% complete response rate.
- FDA accepted a protocol amendment for the pivotal NANORAY-312 study, eliminating interim analysis and modifying final analysis for sooner completion.
- New preclinical data for the Nanoprimer platform was presented at the 2026 AACR Meeting.
Price Impact
More from NBTX